Asymptomatic Diseases

Diseases that do not exhibit symptoms.
Also Known As:
Asymptomatic Conditions; Asymptomatic States; Pre-Symptomatic Diseases; Presymptomatic Diseases; Asymptomatic Condition; Asymptomatic Disease; Asymptomatic State; Condition, Asymptomatic; Conditions, Asymptomatic; Disease, Asymptomatic; Disease, Pre-Symptomatic; Disease, Presymptomatic; Diseases, Asymptomatic; Diseases, Pre-Symptomatic; Diseases, Presymptomatic; Pre-Symptomatic Disease; Presymptomatic Disease
Networked: 198 relevant articles (12 outcomes, 13 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Infection
2. Dyslipidemias (Dyslipidemia)
3. Hypercalcemia (Milk Alkali Syndrome)
4. HIV Infections (HIV Infection)
5. Viremia


1. Tagliavini, Fabrizio: 3 articles (03/2015 - 02/2012)
2. Schnog, John-John B: 3 articles (10/2010 - 07/2008)
3. Padovani, Alessandro: 2 articles (03/2015 - 02/2012)
4. Sorbi, Sandro: 2 articles (03/2015 - 02/2012)
5. Nacmias, Benedetta: 2 articles (03/2015 - 02/2012)
6. Scarpini, Elio: 2 articles (03/2015 - 02/2012)
7. Redaelli, Veronica: 2 articles (03/2015 - 01/2015)
8. Nseir, William: 2 articles (03/2013 - 07/2012)
9. Yue, Zhenyu: 2 articles (01/2012 - 07/2011)
10. Teixeira-Carvalho, Andréa: 2 articles (04/2011 - 08/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Asymptomatic Diseases:
1. Biological Markers (Surrogate Marker)IBA
2. Zidovudine (Retrovir)FDA LinkGeneric
3. Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
4. Gemfibrozil (Lopid)FDA LinkGeneric
5. MetanephrineIBA
6. MercuryIBA
7. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
8. DNA (Deoxyribonucleic Acid)IBA
9. CytokinesIBA
10. glucuronyl glucosamine glycan sulfate (Vessel)IBA
05/28/2010 - "We have found that middle cerebral artery disease confers a lower mortality than vessel-specific ICAD in other intracranial vessels, asymptomatic disease follows a more benign course than symptomatic disease, and that plaque progression or the detection of microemboli on transcranial Doppler may predict poor outcome. "
09/01/2006 - "Here, we outline a proposed treatment algorithm, outlining therapeutic alternatives: (1) PEA should be considered as the first treatment option, where possible; (2) medical intervention is a possible option in inoperable patients and those with significant arteriopathy, although only chronic anticoagulation has been widely used to date (advanced medical treatment options could include prostanoids, endothelin receptor antagonists, or phosphodiesterase-5 inhibitors, but randomized clinical trials are required); (3) pulmonary hypertension is likely to persist after PEA in patients with significant small-vessel arteriopathy, resulting in poor clinical outcome and increased perioperative mortality (medical therapy could also be applied here); (4) anticoagulation therapy and, possibly, advanced medical treatment with careful monitoring may provide benefits in patients with mild or asymptomatic disease; (5) if medical therapy begins to fail, PEA should be offered without delay to avoid progression to severe, secondary arteriopathy; (6) in the absence of severe comorbidity, lung transplantation may be undertaken where PEA has failed, in nonresponders to medical therapy, and in patients with progressive arteriopathy; (7) in patients not eligible for PEA due to collateral and/or surgically inaccessible lesions, balloon angioplasty may be a possible alternative at some centers, but is experimental and requires further assessment. "

Therapies and Procedures

1. Thymectomy
2. Parathyroidectomy
3. Transplantation (Transplant Recipients)
4. Myocardial Revascularization
5. Carotid Endarterectomy